Prelude Therapeutics (PRLD) Net Margin (2024 - 2026)

Prelude Therapeutics has disclosed Net Margin across 3 years of filings, most recently posting 309.54% for Q1 2026.

• Net Margin for Q1 2026 came in at 309.54%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 503.21% (changed N/A YoY), and the FY2025 annual result was 861.33%, up 113458.0% from the prior year.
• Net Margin came in at 309.54% for Q1 2026 at Prelude Therapeutics, down from 307.59% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 307.59% in Q4 2025 to a low of 1145.87% in Q3 2024.
• The 3-year median for Net Margin is 314.12% (2025), against an average of 584.58%.
• Peak annual rise in Net Margin reached 83174 bps in 2025, while the deepest fall reached 53819 bps in 2025.
• Prelude Therapeutics' Net Margin stood at 845.78% in 2024, then jumped by 64 bps to 307.59% in 2025, then decreased by 1 bps to 309.54% in 2026.
• The last three Net Margin figures came in at 309.54% (Q1 2026), 307.59% (Q4 2025), and 314.12% (Q3 2025), per Business Quant data.